Effects of Simvastatin in Patients with Viral Chronic Hepatitis C

Mihăilă, Romeo-Gabriel; Nedelcu, Laurențiu; Frățilă, Ovidiu; Retzler, Laura; Domnariu, Carmen Daniela; Cipăian, Remus-Călin; Rezi, Elena-Cristina; Beca, Corina; Deac, M.

doi:10.5754/hge08074

Cited by 7 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 101 studies identified through our literature search, eight studies fulfilled the inclusion criteria and were accordingly included in our meta‐analysis with one of the studies published as an abstract and one as a letter to the editor . All study authors have been contacted to acquire patient data and complement study information.…”

Section: Resultsmentioning

confidence: 99%

“…Most of the trials were conducted as prospective observational studies, whereas some studies randomized patients and compared the acquired data with a control group . Six of the included studies were conducted in Europe or North America and 2 of them in Japan . Most of the studies included patients with various HCV genotypes and did not provide information about the percentage of patients with advanced fibrosis or cirrhosis.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta‐analysis

Grammatikos

Farnik

Bon

et al. 2014

Journal of Viral Hepatitis

View full text Add to dashboard Cite

Several studies investigating the role of statins and fibrates in chronic hepatitis C virus (HCV) infection offered so far conflicting evidence regarding the antiviral potency of these medications, whereas combination of these drugs with pegylated interferon and ribavirin improved in some trials therapeutic outcome. We conducted a literature search to identify trials that included monoinfected HCV patients, treated with statins or fibrates as monotherapy with the primary end point of our meta-analysis being the quantitative change of HCV-RNA induced by these medications. Logarithmic changes of the viral load (ΔlogVL) and confidence intervals (CIs) were calculated according to the DerSimonian-Laird estimate. Statistical heterogeneity was assessed with the I² statistic. We identified eight observational studies that evaluated the potency of bezafibrate and different statins as monotherapy to induce a significant reduction of HCV-RNA in HCV-monoinfected patients (n = 281). Overall, a significant reduction of viral load with mean 0.19 [log10 IU/mL] (95%-confidence interval, (CI) 0.11-0.28) could be observed when antihyperlipidemic medications were administered. Bezafibrate featured the highest antiviral efficacy (0.45 log10 reduction, 95%-CI, 0.17-0.72) among all medications and fluvastatin (0.20 log10 reduction, 95%-CI, 0.09-0.31) among all statins tested. Based on meta-analysis, fibrates and statins induce a reduction of HCV viral load. We suggest that the addition of statins and fibrates to antiviral regimes, especially in HCV patients with concomitant dyslipidemia, could beside the established reduction of cardiovascular risk increase the potency of antiviral therapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta‐analysis

Grammatikos

Farnik

Bon

et al. 2014

Journal of Viral Hepatitis

View full text Add to dashboard Cite

show abstract

“…Bader and Korba demonstrated that simvastatin exhibited a strong anti-viral activity against HBV in vitro [59]. Mihaila et al reported that simvastatin showed a significant reduction in the level of viremia for the treatment of patients infected with HCV, who had hepatic cytolysis [60]. …”

Section: Discussionmentioning

confidence: 99%

Effect of Statin Treatments on Highly Pathogenic Avian Influenza H5N1, Seasonal and H1N1pdm09 Virus Infections in BALB/c Mice

2012

View full text Add to dashboard Cite

Statins are used to control elevated cholesterol or hypercholesterolemia, but have previously been reported to have antiviral properties. Aims To show efficacy of statins in various influenza virus mouse models. Materials & methods BALB/c mice were treated intraperitoneally or orally with several types of statins (simvastatin, lovastatin, mevastatin, pitavastatin, atorvastatin or rosuvastatin) at various concentrations before or after infection with either influenza A/Duck/ MN/1525/81 H5N1 virus, influenza A/Vietnam/1203/2004 H5N1 virus, influenza A/ Victoria/3/75 H3N2 virus, influenza A/NWS/33 H1N1 virus or influenza A/CA/04/09 H1N1pdm09 virus. Results The statins administered intraperitoneally or orally at any dose did not significantly enhance the total survivors relative to untreated controls. In addition, infected mice receiving any concentration of statin were not protected against weight loss due to the infection. None of the statins significantly increased the mean day of death relative to mice in the placebo treatment group. Furthermore, the statins had relatively few ameliorative effects on lung pathology or lung weights at day 3 and 6 after virus exposure, although mice treated with simvastatin did have improved lung function as measured by arterial saturated oxygen levels in one experiment. Conclusion Statins showed relatively little efficacy in any mouse model used by any parameter tested.

show abstract

“…Treatment of patients with different statins (i.e. lovastatin, simvastin, or fluvastin) resulted in diverse effects on HCV infection, ranging from an absence of antiviral effect to a modest improvement of sustained antiviral response, or a reduction of viremia [172,173,[187][188][189]. Beneficial effects derived from treatment with statins of infection with diverse influenza strains have also been reported in animal models and human studies [170,171], although other studies do not support these conclusions [190].…”

Section: Targeting Cholesterol As An Antiviral Strategymentioning

confidence: 90%

Lipid Involvement in Viral Infections: Present and Future Perspectives for the Design of Antiviral Strategies

Martín-Acebes¹,

Vázquez-Calvo²,

Caridi³

et al. 2013

Lipid Metabolism

View full text Add to dashboard Cite

Effects of Simvastatin in Patients with Viral Chronic Hepatitis C

Abstract: In this study, more than half of the patients chronically infected with the hepatitis C virus, who had hepatic cytolysis and were treated with simvastatin, showed a significant reduction in the level of viremia.

Cited by 7 publications

References 0 publications

The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta‐analysis

The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta‐analysis

Effect of Statin Treatments on Highly Pathogenic Avian Influenza H5N1, Seasonal and H1N1pdm09 Virus Infections in BALB/c Mice

Lipid Involvement in Viral Infections: Present and Future Perspectives for the Design of Antiviral Strategies

Contact Info

Product

Resources

About